Rare TumorsPub Date : 2023-01-01DOI: 10.1177/20363613231189984
David J Benjamin, Arash Rezazadeh Kalebasty
{"title":"Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies.","authors":"David J Benjamin, Arash Rezazadeh Kalebasty","doi":"10.1177/20363613231189984","DOIUrl":"https://doi.org/10.1177/20363613231189984","url":null,"abstract":"<p><p>Urachal cancer is a rare genitourinary malignancy that arises from the embryologic remnant of the urachus. The malignancy is considered to be aggressive, with no clear consensus on appropriate management for advanced disease. Although traditionally considered to be related to bladder cancer given its embryologic origin, several next generation sequencing studies have revealed the genomic profile of this genitourinary malignancy most closely resembles colorectal cancer. Moreover, these studies have identified potentially actionable mutations including EGFR, KRAS and MET. In addition, recent data suggests that immunotherapy may benefit some patients with advanced urachal cancer. Nonetheless, continued research is warranted to better understand how to treat this rare genitourinary cancer.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231189984"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/c0/10.1177_20363613231189984.PMC10350764.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2023-01-01DOI: 10.1177/20363613231163730
Harper E Niver, Edward Foxhall, Anup Lahiry
{"title":"KEYNOTE-522 and male spindle cell carcinoma of the breast: A case report.","authors":"Harper E Niver, Edward Foxhall, Anup Lahiry","doi":"10.1177/20363613231163730","DOIUrl":"https://doi.org/10.1177/20363613231163730","url":null,"abstract":"<p><p>Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more aggressive biological behavior with increased risk of recurrence and death due to disease compared to triple negative breast cancers. There is no treatment guideline for management of MBC due to the rarity of the disease. Instead, treatment is theorized based off success with other types of aggressive breast and metaplastic cancers of different tissue. We present the first known case report of male spindle cell carcinoma of the breast treated with KEYNOTE-522 regimen. Therapy included a first phase with pembrolizumab (dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin and second phase, with four cycles of pembrolizumab with doxorubicin-cyclophosphamide.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231163730"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/cd/10.1177_20363613231163730.PMC10021088.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9152989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2023-01-01DOI: 10.1177/20363613231160699
Divya Khosla, Rakesh Kapoor, Aditya K Singla, Kannan Periasamy, Shikha Goyal, Renu Madan, Narendra Kumar, Arunanshu Behera, Shrawan K Singh, Sanjay K Bhadada, Rama Walia
{"title":"Treatment outcomes of adjuvant radiotherapy in adrenocortical carcinoma - A 13-years experience from a tertiary care centre.","authors":"Divya Khosla, Rakesh Kapoor, Aditya K Singla, Kannan Periasamy, Shikha Goyal, Renu Madan, Narendra Kumar, Arunanshu Behera, Shrawan K Singh, Sanjay K Bhadada, Rama Walia","doi":"10.1177/20363613231160699","DOIUrl":"https://doi.org/10.1177/20363613231160699","url":null,"abstract":"<p><strong>Purpose: </strong>Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignant neoplasm, usually diagnosed in advanced stage. Role and efficacy of adjuvant radiotherapy has not been well defined. The objective of this study is to describe the various clinical characteristics and prognostic factors affecting the survival of ACC along with the role radiotherapy on overall survival and relapse free survival.</p><p><strong>Methods: </strong>A retrospective analysis of 30 patients registered between 2007 and 2019 was carried out. The medical records containing clinical and treatment details were analysed. Data was analysed using SPSS 25.0. Survival curves were computed using Kaplan-Meier method. Univariate and multivariate analyses were performed to analyze the prognostic factors affecting the outcome. A <i>p</i> value of less than 0.05 was considered to be statistically significant.</p><p><strong>Results: </strong>The median age of patients was 37.5 years (range, 5-72 years). 20 patients were females. Twenty-six patients had advanced stage (III/IV) disease while only four patients presented in early stage. Twenty-six patients underwent total adrenalectomy. Eighty three percent patients received adjuvant radiation therapy. The median follow up was 35.5 months (range, 7 monthss-132months). The estimated three- and 5-years overall survival (OS) was 67.2% and 23.3%, respectively. Capsular invasion and positive margins were the independent prognostic factors influencing both OS and relapse free survival (RFS). Out of 25 patients who received adjuvant radiation, only three patients had local relapse.</p><p><strong>Conclusion: </strong>ACC is a rare and aggressive neoplasm with majority of patients presenting in advanced stage. Surgical resection with negative margins remains the mainstay of treatment. Capsular invasion and positive margins are independent prognostic factors for survival. Adjuvant radiation reduces the risk of local relapse and is well tolerated. Radiation can be used effectively in adjuvant and palliative settings in ACC.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231160699"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/21/10.1177_20363613231160699.PMC9969472.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10824322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2023-01-01DOI: 10.1177/20363613231193566
Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui
{"title":"Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.","authors":"Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui","doi":"10.1177/20363613231193566","DOIUrl":"https://doi.org/10.1177/20363613231193566","url":null,"abstract":"The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231193566"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/f3/10.1177_20363613231193566.PMC10392166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2022-11-01eCollection Date: 2022-01-01DOI: 10.1177/20363613221135015
Yongguo Xie, Ke Qin, Xueke Du, Shaopeng Ming, Lianmei Li, Chuangsheng Huang
{"title":"Primary tracheal obstruction caused by adenoid cystic carcinoma during pregnancy: A case report.","authors":"Yongguo Xie, Ke Qin, Xueke Du, Shaopeng Ming, Lianmei Li, Chuangsheng Huang","doi":"10.1177/20363613221135015","DOIUrl":"https://doi.org/10.1177/20363613221135015","url":null,"abstract":"<p><p>The incidence of malignant tumors diagnosed during pregnancy is increasing, often ascribed to the recently recognized trend that many women are postponing childbirth. Although early diagnosis is optimal for both mothers and fetuses, the diagnosis of malignant tumors during pregnancy is often delayed until an advanced stage, because generalized symptoms of pregnancy and malignancy may overlap, such as shortness of breath, chest or abdominal discomfort. The study patient was 21 years old, and 31 weeks-pregnant when she was diagnosed with primary tracheal adenoid cystic carcinoma (ACC). The patient initially presented with dyspnea and decreased blood oxygen saturation and underwent a cesarean section on the first night of hospitalization, resulting from fetal distress. This case report intended to investigate potential barriers to the timely diagnosis of tracheal ACC and consider optimal management strategies when it is diagnosed during pregnancy.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221135015"},"PeriodicalIF":0.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/9b/10.1177_20363613221135015.PMC9629539.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40685690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2022-11-01eCollection Date: 2022-01-01DOI: 10.1177/20363613221123951
Vishal Mago, Arush Pasricha
{"title":"Reconstruction options in recurrent dermatofibrosarcoma protuberans:A scoping review.","authors":"Vishal Mago, Arush Pasricha","doi":"10.1177/20363613221123951","DOIUrl":"https://doi.org/10.1177/20363613221123951","url":null,"abstract":"<p><strong>Background: </strong>This review will outline the evaluation, diagnosis, and management of dermatofibrosarcoma protuberans and emphasizes multidisciplinary role of nurses, plastic surgeons and radiation oncologist in this recurrent metastatic lesion. It pinpoints affected population at risk, clinical features, and reconstruction options. No analytical research has been done in this area.</p><p><strong>Material and methods: </strong>A scoping review of patients of DFSP who underwent reconstruction after excision of tumors was performed in the Department of Burn and Plastic Surgery, AIIMS Rishikesh. It used a five framework approach. A review of 85 similar cases reported in the literature have been scrutinized in relation to the reconstruction options, sites of the tumor, margins of excision and recurrence.</p><p><strong>Results: </strong>85 full length English studies were included out of the 445 cases found in Pubmed and related search engines to reveal various reconstructive options in reconstruction of DFSP defects. Present scoping review identifies free anterolateral thigh flap to be useful in 7 review articles followed by propeller flaps in 3 isolated case reports. 2 cases of free latissimus dorsi flap were used for reconstruction of abdominal defects.</p><p><strong>Conclusion: </strong><i>All patients should undergo a strict screening protocol where the health personnel can play a crucial role by educating parents on the follow up and report new lesions as early as possible. All operated tumor patients can be given safety tips and education on care and risks after reconstruction with skin flaps or skin grafting</i>. A multidisciplinary approach between the surgeon, nurse and radiation oncologist is needed for effective management of these lesions.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221123951"},"PeriodicalIF":0.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/11/10.1177_20363613221123951.PMC9630893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40685689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2022-10-18eCollection Date: 2022-01-01DOI: 10.1177/20363613221135987
Safia Yahiaoui, Asma Ghorbel, Khadija Ben Zid, Semia Zarraa, Lina Kchaou, FidaNoubigh, Wael Kaabia, Fadoua Bouguerra, Alia Mousli, Rim Abidi, Amani Yousfi, Boujelbene Nadia, Chiraz Nasr
{"title":"Spontaneous regression of an orbital Langerhans cell histiocytosis after biopsy: A case report. Spontaneous regression of an orbital Langerhans cell histiocytosis.","authors":"Safia Yahiaoui, Asma Ghorbel, Khadija Ben Zid, Semia Zarraa, Lina Kchaou, FidaNoubigh, Wael Kaabia, Fadoua Bouguerra, Alia Mousli, Rim Abidi, Amani Yousfi, Boujelbene Nadia, Chiraz Nasr","doi":"10.1177/20363613221135987","DOIUrl":"https://doi.org/10.1177/20363613221135987","url":null,"abstract":"<p><p>Langerhans histiocytosis or Langerhans cell histiocytosis (LCH) is a rare benign pathology representing less than 1% of orbital tumors. It can cause either localized or generalized lesions, leading to the destruction of hard and soft tissues. Eosinophilic granuloma is the most benign form and the predominant clinical presentation of LCH. We report a case of eosinophilic granuloma with orbital involvement in an 18-year-old male patient. Orbital radiotherapy was initially planned, but finally it was not performed due to a spontaneous regression of the lesion after the incisional biopsy. The presented case supports an expectant attitude given the possibility of a spontaneous regression after the biopsy, especially in small lesions. However, long-term follow-up is essential given the risk of recurrence.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221135987"},"PeriodicalIF":0.9,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/56/10.1177_20363613221135987.PMC9583201.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2022-10-03eCollection Date: 2022-01-01DOI: 10.1177/20363613221130155
Sungchul Ko, Kye Hoon Park, Ji-Hye Lee, Ki Nam Park
{"title":"A case of initially metastasizing pleomorphic adenoma of parotid gland.","authors":"Sungchul Ko, Kye Hoon Park, Ji-Hye Lee, Ki Nam Park","doi":"10.1177/20363613221130155","DOIUrl":"https://doi.org/10.1177/20363613221130155","url":null,"abstract":"<p><p>Metastasis of pleomorphic adenoma (PA) is rare and usually presented as a locoregional recurrence developed many years after excision of the primary tumor although the PA is the most common neoplasm in the parotid gland. We described a case of a 48-year-old male with a parotid tumor with multiple enlarged ipsilateral lymph nodes which suggested a malignancy. The tumors had been neither evaluated nor excised and preoperative evaluation revealed benign PA in both lesions. After the complete surgical excision, the final pathology was notable for benign PA with metastasis to regional lymph nodes. At 1 year follow up he was clinically and radiographically free of disease. This implies that pleomorphic adenoma can occur as initially metastasis to regional lymph node even though benign neoplasm.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221130155"},"PeriodicalIF":0.9,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/bd/10.1177_20363613221130155.PMC9536096.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33496269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Very low-dose radiation therapy for management of inflammatory myofibroblastic tumor of the lung.","authors":"Nimeh Najjar, Hamel Patel, Scott Steinberg, Brett Baskovich, Stephanie Rothweiler, Bradford Hoppe","doi":"10.1177/20363613221106270","DOIUrl":"https://doi.org/10.1177/20363613221106270","url":null,"abstract":"<p><p>Inflammatory myofibroblastic tumor (IMT) is an uncommon chest pathology. Treatment primarily focuses on surgical resection for diagnostic and therapeutic purposes. However, there are instances in which alternative therapies with steroids, chemotherapy, or radiation are necessary. We discuss a case of recurrent IMT for which very low dose radiation proved an effective treatment.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221106270"},"PeriodicalIF":0.9,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/a4/10.1177_20363613221106270.PMC9290091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rare TumorsPub Date : 2022-07-08eCollection Date: 2022-01-01DOI: 10.1177/20363613221112432
Joshua A Cuoco, Andrew C Strohman, Brittany M Stopa, Michael S Stump, John J Entwistle, Mark R Witcher, Adeolu L Olasunkanmi
{"title":"Supratentorial cortical ependymoma: A systematic literature review and case illustration.","authors":"Joshua A Cuoco, Andrew C Strohman, Brittany M Stopa, Michael S Stump, John J Entwistle, Mark R Witcher, Adeolu L Olasunkanmi","doi":"10.1177/20363613221112432","DOIUrl":"https://doi.org/10.1177/20363613221112432","url":null,"abstract":"<p><p>Cortical ependymomas are currently not considered a subgroup of supratentorial ependymomas; however, there is a growing body of literature investigating the natural history of these lesions compared to supratentorial ependymomas. We performed a systematic literature review of cortical ependymomas with a focus on the natural history, clinical characteristics, and clinical outcomes of these lesions as compared to supratentorial ependymomas. Our search revealed 153 unique cases of cortical ependymomas. The mean age on presentation was 21.2 years. Males and females comprised 58.8% (90/153) and 41.2% (63/153) of cases, respectively. The most common presenting symptom was seizure activity occurring in 44.4% of the cohort (68/153). The recently recognized <i>C11orf95-RELA</i> fusion was identified in 13.7% of the cohort (21/153) and 95.5% of cases (21/22) reporting molecular characterization. World Health Organization grades 2 and 3 were reported in 52.3% (79/151) and 47.7% (72/151) of cases, respectively. The frontal lobe was involved in the majority of cases (54.9%, 84/153). Gross total resection was achieved in 80.4% of cases (123/153). Tumor recurrence was identified in 27.7% of cases (39/141). Mean clinical follow-up was 41.3 months. Mean overall survival of patients who expired was 27.4 months whereas mean progression-free survival was 15.0 months. Comparatively, cortical ependymomas with <i>C11orf95</i>-<i>RELA</i> fusions and supratentorial ependymomas with <i>C11orf95 RELA</i> fusions exhibited differing clinical outcomes. Further studies with larger sample sizes are necessary to investigate the significance of <i>RELA</i> fusions on survival in cortical ependymomas and to determine whether cortical ependymomas with <i>C11orf95</i>-<i>RELA</i> fusions should be classified as a distinct entity.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221112432"},"PeriodicalIF":0.9,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/87/10.1177_20363613221112432.PMC9274435.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40506725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}